The role of somatostatin analogues in the treatment of neuroendocrine tumours.

The role of somatostatin analogues in the treatment of neuroendocrine tumours.

Neuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands), in endocrine islets (within the thyroid or pancreas) as well as in endocrine cells dispersed between exocrine cells through...

Full description

Bibliographic Details
Main Authors:	Grozinsky-Glasberg, S, Grossman, AB, Korbonits, M
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
by: Kaltsas, G, et al.
Published: (2005)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
by: King, C, et al.
Published: (1993)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
by: Ur, E, et al.
Published: (1993)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
by: Cakir, M, et al.
Published: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
by: Cakir, M, et al.
Published: (2010)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
by: Gupta, P, et al.
Published: (2014)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
by: Sen Gupta, P, et al.
Published: (2014)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
by: Chahal, H, et al.
Published: (2011)

Update on neuroendocrine tumours
by: Grossman, AB
Published: (2012)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
by: Carroll, P, et al.
Published: (2003)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
by: Hubina, E, et al.
Published: (2006)

The role of chemotherapy management of malignant in the nonsurgical neuroendocrine tumours
by: Kaltsas, G, et al.
Published: (2001)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2001)

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
by: Kaltsas, G, et al.
Published: (2014)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
by: Chahal, H, et al.
Published: (2010)

MRI of pancreatic neuroendocrine tumours.
by: Owen, N, et al.
Published: (2001)

Antiangiogenic effects of somatostatin analogues.
by: García de la Torre, N, et al.
Published: (2002)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2010)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
by: Ur, E, et al.
Published: (1992)

Intracardiac metastases from neuroendocrine tumours.
by: Drake, WM, et al.
Published: (1997)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
by: Den Gupta, P, et al.
Published: (2011)

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.
by: Druce, MR, et al.
Published: (2010)

Neuroendocrine tumours: a hope and a prayer.
by: Grossman, A
Published: (2009)

The potential role of D(2) dopamine receptors as a target in the management of neuroendocrine tumors.
by: Ribeiro-Oliveira, A, et al.
Published: (2008)

Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs)
by: Grozinsky-Glasberg, S, et al.
Published: (2020)

Gastroenteropancreatic neuroendocrine tumours.
by: Modlin, I, et al.
Published: (2008)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
by: Kaltsas, G, et al.
Published: (2002)

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001)

Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review.
by: Dworakowska, D, et al.
Published: (2009)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
by: Jenkins, P, et al.
Published: (2000)

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
by: Kwekkeboom, D, et al.
Published: (2009)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2004)

The role of DNA methylation in human pancreatic neuroendocrine tumours
by: English, KA, et al.
Published: (2023)

Genetics of neuroendocrine and carcinoid tumours.
by: Leotlela, P, et al.
Published: (2003)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
by: Grozinsky-Glasberg, S, et al.
Published: (2011)

Growth hormone-releasing peptides (GHRP) and their analogues
by: Korbonits, M, et al.
Published: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
by: Korbonits, M, et al.
Published: (1996)

Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors
by: Lines, K, et al.
Published: (2017)